The global market for osteoporosis treatments is forecast to grow from $10.5 billion in 2023 to $17.9 billion by 2033, according to GlobalData.
This represents a compound annual growth rate of 5.4% across mature markets.
GlobalData's research highlights the growing popularity of costly anabolic therapies and an expanding patient population due to aging demographics as key drivers of this market growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze